Results 181 to 190 of about 202,668 (261)

Craniofacial Resection for Advanced Cutaneous Squamous Cell Carcinoma: Results From the 2nd International Collaborative Case‐Series

Head &Neck, EarlyView.
ABSTRACT Background Robust outcome data for anterior skull base cutaneous squamous cell carcinoma (cSCC) are limited, particularly as emerging therapies reshape management. We evaluated survival and prognostic factors following craniofacial resection. Methods Retrospective multi‐institutional case‐series (1995–2015) of patients who underwent skull base
Michael J. C. Schachtel, Benedict J. Panizza, James J. Bowman, Catherine Barnett, Cristina Valero, Ian Ganly, Snehal G. Patel, Helena Levyn, Dauren Adilbay, Alana Eagan, Marc A. Cohen, Lillian A. Boe, Junting Zheng, Mithat Gonen, Prathamesh Pai, Paolo Castelnuovo, Fang Ju Gao, Cesare Piazza, Piero Nicolai, Luiz P. Kowalski, Ronaldo N. Toledo, Claudio Cernea, Sergio Goncalves, Dan M. Fliss, John R. de Almeida, Ian Witterick, Philippe Herman, Walter Fontanella, Gregorio Sanchez Aniceto, Alvaro Rivero Calle, Sefik Hosal, Serdar Ozer, Subramania Iyer, Richard J. Harvey, C. Rene Leemans, Jan‐Jaap Hendrickx, Marcelo Figari, Luis Boccalatte, Ken Ichi Nibu, Peter Clarke, Catherine Rennie, Yiming Zhu, Rodney J. Schlosser, Fernando L. Dias, Zoukaa Sargi, Shahzada Ahmed, Wojciech Golusinski, Se Heon Kim, Shirley Y. Su, Shaan M. Raza, Franco DeMonte, Ehab Hanna, Jatin P. Shah   +52 more
wiley   +1 more source

Non-Cisplatin Concurrent Systemic Therapy with Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Network Meta-Analysis of Randomized Clinical Trials. [PDF]

Cancers (Basel)
Schöbel KS, Schoele AJ, Wurschi G, Pietschmann K, Römer M.   +4 more
europepmc   +1 more source

Correction: Overcoming limitations of cisplatin therapy by additional treatment with the HSP90 inhibitor onalespib. [PDF]

Front Oncol
Mortensen ACL, Mohajershojai T, Hariri M, Pettersson M, Spiegelberg D.   +4 more
europepmc   +1 more source

Function of molecular-weight-optimized Astragalus polysaccharides in cisplatin-caused acute kidney injury: mechanisms centered on gut microbiota regulation and precise treatment approaches. [PDF]

Front Microbiol
Li H, Li H, Wu R, Zhong M.
europepmc   +1 more source

Pharmacological effects of gastrodin: Insight into neurological diseases and mechanism in ferroptosis and pyroptosis

Ibrain, Volume 11, Issue 1, Page 74-83, Spring 2025.
Pharmacological effects of gastrodin include prevention and treatment of cognitive decline and reperfusion injuries, anticonvulsion, antiepilepsy, antidepressants, and analgesia, which are related to antiferroptosis and antipyroptosis. Abstract Gastrodin, as an effective monomer of gastrodia elata, plays a significant role in anti‐inflammatory ...
Xue Zheng, Jing Li, Zhao‐Qiong Zhu
wiley   +1 more source

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle‐Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab‐Gemcitabine‐Cisplatin Versus Gemcitabine‐Cisplatin: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials

International Journal of Cancer, EarlyView.
Optimizing neoadjuvant therapy for muscle‐invasive bladder cancer patients who are eligible for cisplatin remains difficult, owing particularly to high toxicity and recurrence rates. This meta‐analysis compared dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) against durvalumab plus gemcitabine‐cisplatin (D‐GC) and GC alone ...
Maurin Helen Mangold, Gloria Baumann, Victoria Luise Simone Wieland, Nicolas Carl, Luisa Vivienne Renner, Alexander Studier‐Fischer, Hanna Menold, Stefanie Zschäbitz, Frederik Wessels, Niklas Westhoff, Maurice Stephan Michel, Karl‐Friedrich Kowalewski, Caelán Max Haney‐Aubert   +12 more
wiley   +1 more source

Comparison of pharmacovigilance and mechanism analysis of the vascular toxicity caused by platin-based chemotherapy: integration of FAERS analysis, network pharmacology, and endothelial validation. [PDF]

Ther Adv Drug Saf
Chen Y, Wang C, Jiang P, Chen Y, Zhang T, Cai S.   +5 more
europepmc   +1 more source

Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR‐Mutated Locally Advanced or Metastatic Lung Cancer

International Journal of Cancer, EarlyView.
Non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations often exhibit significant tumor reduction following tyrosine kinase inhibitor (TKI) therapy. Residual tumors frequently remain, however, leading to drug resistance and disease progression.
Fedor Moiseenko, Daniil Stroyakovskiy, Evgeniy Levchenko, Mikhail Fedyanin, Albina Gabina, Ani Oganesian, Sergey Belukhin, Maria Stepanova, Ekaterina Stepanova, Elizaveta Artemyeva, Alexander Myslik, Nikita Volkov, Alexei Bogdanov, Tatiana Shuginova, Kirill Kryukov, Valeria Kheinshtein, Arif Allakhverdiev, Ivan Zaberegniy, Yana Akhmadiyarova, Mikhail Popov, Anastasiya Danilova, Dmitriy Sehniaidze, Nikita Savelov, Nikita Levchenko, Evgeniy Slugin, Olga Lopushanskaya, Ekaterina Kuligina, Svetlana Aleksakhina, Aglaya Iyevleva, Alexandr Ivantsov, Vladimir Moiseyenko, Evgeny Imyanitov   +31 more
wiley   +1 more source